Elisabetta Galbiati

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Correction: HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy.

Correction: HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy.

Journal: Frontiers in immunology

Published: June 12, 2025

HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy.

HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy.

Journal: Frontiers in immunology

Published: December 17, 2024

The Vault Nanoparticle: A Gigantic Ribonucleoprotein Assembly Involved in Diverse Physiological and Pathological Phenomena and an Ideal Nanovector for Drug Delivery and Therapy.

The Vault Nanoparticle: A Gigantic Ribonucleoprotein Assembly Involved in Diverse Physiological and Pathological Phenomena and an Ideal Nanovector for Drug Delivery and Therapy.

Journal: Cancers

Published: January 11, 2021

Functionalization of colloidal nanoparticles with a discrete number of ligands based on a "HALO-bioclick" reaction.

Functionalization of colloidal nanoparticles with a discrete number of ligands based on a "HALO-bioclick" reaction.

Journal: Chemical communications (Cambridge, England)

Published: September 29, 2020

Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.

Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.

Journal: Journal of medicinal chemistry

Published: November 12, 2019

Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.

Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.

Journal: Journal of cancer research and clinical oncology

Published: July 27, 2019

Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells.

Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells.

Journal: Nanoscale advances

Published: April 12, 2019

Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.

Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.

Journal: Journal of cancer research and clinical oncology

Published: September 04, 2018

A fast and straightforward procedure for vault nanoparticle purification and the characterization of its endocytic uptake.

A fast and straightforward procedure for vault nanoparticle purification and the characterization of its endocytic uptake.

Journal: Biochimica et biophysica acta. General subjects

Published: April 24, 2018

Negatively charged silver nanoparticles with potent antibacterial activity and reduced toxicity for pharmaceutical preparations.

Negatively charged silver nanoparticles with potent antibacterial activity and reduced toxicity for pharmaceutical preparations.

Journal: International journal of nanomedicine

Published: April 15, 2017

Theranostic Nanocages for Imaging and Photothermal Therapy of Prostate Cancer Cells by Active Targeting of Neuropeptide-Y Receptor.

Theranostic Nanocages for Imaging and Photothermal Therapy of Prostate Cancer Cells by Active Targeting of Neuropeptide-Y Receptor.

Journal: Bioconjugate chemistry

Published: November 05, 2016

"Blind" targeting in action: From phage display to breast cancer cell targeting with peptide-gold nanoconjugates.

"Blind" targeting in action: From phage display to breast cancer cell targeting with peptide-gold nanoconjugates.

Journal: Pharmacological research

Published: March 25, 2016

Showing 1-12 of 25

Last Updated: 09/26/2026